Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Janssen Research & Development
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
Amivantamab + pemetrexed is an investigational combination therapy consisting of the bispecific antibody amivantamab and the antifolate chemotherapy agent pemetrexed. Amivantamab targets both the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition (MET) receptor, inhibiting ligand binding and receptor dimerization to disrupt tumor growth signaling. Pemetrexed is a small molecule that inhibits multiple folate-dependent enzymes, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby blocking nucleotide synthesis. This combination is primarily being evaluated for the treatment of leptomeningeal metastasis arising from EGFR-mutated non-small cell lung cancer (NSCLC), utilizing a novel administration strategy where pemetrexed is delivered both systemically and intrathecally to overcome the blood-brain barrier.
- Other names
- amivantamab plus pemetrexed
02
Targets
DHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)GART (GAR transformylase)MET (Mesenchymal-epithelial transition factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on amivantamab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + pemetrexed.